FDA official logo
GSRS logoPFDA official logo

TRASTUZUMAB DERUXTECAN

UNII:5384HK7574
Formula:
Preferred Substance Name:TRASTUZUMAB DERUXTECAN

  • 1826843-81-5
  • DS-8201
  • ENHERTU
  • FAM-TRASTUZUMAB DERUXTECAN-NXKI
  • IMMUNOGLOBULIN G1, ANTI-(HUMAN TYROSINE KINASE RECEPTOR ERBB2) (HUMAN-MUS MUSCULUS MONOCLONAL DS20151130 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL DS20151130 LIGHT CHAIN, DIMER, THIOETHER WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)GLYCYLGLYCYL-L-PHENYLALANYL-N-((2-(((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-2-OXOETHOXY)METHYL)GLYCINAMIDE
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (METASTATIC LYMPH NODE GENE 19 PROTEIN, PROTO-ONCOGENE C-ERBB-2, CD340 ANTIGEN))HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO DERUXTECAN, A CAMPTOTHECIN DERIVATIVE AND A LINKER.GAMMA.1 HEAVY CHAIN (1-450) (HUMANIZED VH (HOMO SAPIENS IGHV3-66*01 (82%) (IGHD)-IGHJ4*02) (8.8.13) (1-120)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(217)) (121-450)) (223-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-214') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (86%) IGKJ1*01)(6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), DIMER (229-229'':232-232'')-BISDISULFIDE, AN AVERAGE OF 8 CYSTEIN RESIDUES ARE NOT INVOLVED IN DISULFIDE BRIDGE AND S SUBSTITUTED WITH (3RS)-1-((10S)-10-BENZYL-1-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-1,6,9,12,15,18-HEXAOXO-3-OXA-5,8,11,14,17-PENTAAZATRICOSAN-23-YL)-2,5-DIOXOPYRROLIDIN-3-YL
  • TRASTUZUMAB DERUXTECAN [INN]
  • TRASTUZUMAB DERUXTECAN [JAN]
  • TRASTUZUMAB DERUXTECAN [USAN]
  • TRASTUZUMAB DERUXTECAN [WHO-DD]
  • TRASTUZUMAB DERUXTECAN NXKI [WHO-DD]
  • TRASTUZUMAB DERUXTECAN-NXKI




UNII - 5384HK7574 | UNII Search Service